We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia.
- Authors
Cacho, Judit; Burgos, Elena; Molina, María; Villega, Andrís; Pérez, Mónica; Cañas, Laura; Taco, Omar; Juega, Javier; Lauzurica, Ricardo
- Abstract
Background: Remdesivir is the only antiviral treatment that has been shown to be useful against SARS-CoV-2 infection. It shorts hospitalization time compared to placebo. Its effects in Kidney transplant (KT) patients are limited to some published cases. Methods: We performed a retrospective observational study that included all KT patients admitted between August 01, 2020 and December 31, 2020 with SARS-CoV-2 pneumonia who received remdesivir. The objective of this study was to describe the experience of a cohort of KT patients treated with remdesivir. Discussion: A total of 37 KT patients developed SARS-CoV-2 infection, 7 of them received treatment with remdesivir. The rest of the patients did not receive the drug due to either CKD-EPI less than 30 mL/min or they did not present clinical criteria. In addition to remdesivir, all pacients received dexamethasone and anticoagulation therapy. 4 were men, the median age was 59 (53-71) years. Median time from transplantation was 43 (16-82) months. Chest X-rays of all patients showed pulmonary infiltrates and required low oxygen flow therapy upon admission, requiring high flow nasal therapy in 3 cases. Only 2 cases presented deterioration of the graft function, not requiring hemodialysis in any case, and all recovered renal function at hospital discharge. 2 patients rise up 1.5 times the liver function test. No patient died or required admission to the critical care unit. Median days of admission was Conclusions: Our study suggests that the use of remdesivir could be useful in KT patients with SARS-CoV-2 pneumonia without side effects. Additional studies are necessary with a larger number of patients to improve the knowledge of this drug in SARS-CoV-2 infection.
- Subjects
KIDNEY transplantation; REMDESIVIR; INTENSIVE care units; SARS-CoV-2; LIVER function tests
- Publication
Nefrologia, 2022, Vol 42, Issue 3, p311
- ISSN
0211-6995
- Publication type
Article
- DOI
10.1016/j.nefroe.2022.07.006